Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors

被引：0

作者：

De Miguel, M. ^{[1
]}

Landa Magdalena, A. ^{[2
]}

Moreno Garcia, V. ^{[3
]}

Gambardella, V. ^{[4
]}

Menis, J. ^{[5
]}

Daniele, G. ^{[6
]}

El-Khoueiry, A. B. ^{[7
]}

Spira, A. I. ^{[8
]}

Gravina, A. ^{[9
,10
]}

Olszanski, A. J. ^{[11
]}

Rapaic, O. ^{[12
]}

Li, J. ^{[13
]}

Poullain, H. ^{[14
]}

Margall, G. ^{[14
]}

Wong, G. ^{[15
]}

Hedrich, W. ^{[16
]}

Pollard, J. Russella ^{[15
]}

Gan, J. ^{[17
]}

Shi, X. ^{[18
]}

Andtbacka, R. H. I. ^{[19
]}

机构：

[1] Hosp Univ HM Sanchinarro, CIOCC Ctr Integral Oncol Clara Campal, Early Phase Clin Trial Unit, Madrid, Spain

[2] Clin Univ Navarra, Dept Med Oncol, Madrid, Spain

[3] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain

[4] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[5] AOU Integrata Verona Osped Borgo Roma, Med Oncol, Verona, Italy

[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Phase Unit 1, Rome, Italy

[7] USC Univ Southern Calif, Keck Sch Med, Med Oncol Div, Los Angeles, CA USA

[8] Virginia Canc Specialist, Res Dept, Fairfax, VA USA

[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Dipartimento Ric Traslaz, Naples, Italy

[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Serv Percorsi Oncol, Naples, Italy

[11] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA

[12] HiFiBiO Inc, Clin Operat, Cambridge, MA USA

[13] HiFiBiO Therapeut Inc, Dis Biol, Cambridge, MA USA

[14] HiFiBio SAS, Translat Med, Paris, France

[15] HiFiBiO Therapeut Inc, Translat Med, Cambridge, MA USA

[16] HiFiBiO Therapeut Inc, Clin Pharmacol, Cambridge, MA USA

[17] HiFiBiO Therapeut Inc, Res, Cambridge, MA USA

[18] HiFiBiO Therapeut, Clin Dev, Shanghai, Peoples R China

[19] HiFiBiO Therapeut Inc, Clin Dev, Cambridge, MA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1065

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1006P

引用

页码：S684 / S684

页数：1

共 50 条

[41] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
Coward, Jermaine
Mislang, Anna Rachelle Austria
Frentzas, Sophia
Lemech, Charlotte Rose
Nagrial, Adnan
Jin, Xiaoping
Li, Baiyong
Wang, Zhongmin Maxwell
Kwek, Kon Yew
Xia, Yu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
Huang, Jing
Mo, Hongnan
Wu, Dawei
Chen, Xuelian
Ma, Lanying
Lan, Bo
Qu, Dong
Yang, Qing
Xu, Binghe
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43] Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
Liu, Rujiao
Li, Wenhua
Meng, Yanchun
Gao, Shuiping
Zhang, Jian
Hu, Xichun
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[44] AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
Lu, Y.
Gong, Y.
Kang, J-H.
Ree, J. Whan
Chen, X.
Lin, X.
Zhang, J.
Borghaei, H.
ANNALS OF ONCOLOGY, 2022, 33 : S103 - S103
[45] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Shimizu, Toshio
Seto, Takashi
Hirai, Fumihiko
Takenoyama, Mitsuhiro
Nosaki, Kaname
Tsurutani, Junji
Kaneda, Hiroyasu
Iwasa, Tsutomu
Kawakami, Hisato
Noguchi, Kazuo
Shimamoto, Takashi
Nakagawa, Kazuhiko
INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
[46] Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.
Desai, Jayesh
Voskoboynik, Mark
Markman, Ben
Hou, Jeannie
Zeng, Dewan
Meniawy, Tarek
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Toshio Shimizu
Takashi Seto
Fumihiko Hirai
Mitsuhiro Takenoyama
Kaname Nosaki
Junji Tsurutani
Hiroyasu Kaneda
Tsutomu Iwasa
Hisato Kawakami
Kazuo Noguchi
Takashi Shimamoto
Kazuhiko Nakagawa
Investigational New Drugs, 2016, 34 : 347 - 354
[48] AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
Frentzas, Sophia
Meniawy, Tarek
Kao, Steven Chuan-Hao
Wang, Ruihua
Zuo, Yunxia
Zheng, Hao
Tan, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.
Oh, Do-Youn
Park, John J.
Lee, Keun Wook
Kim, Seung Tae
Sriuranpong, Virote
Rha, Sun Young
Yoo, Changhoon
Keam, Bhumsuk
Sabanathan, Dhanusha
Kim, Se Hyun
Park, Joon Oh
Parinyanitikul, Napa
Kim, Min Hwan
Kim, Kyu-Pyo
Kim, Myungsuk
Yoon, Jaebong
Lee, Han Seung
Ock, Chan-Young
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results
Lakhani, Nehal J.
Hamid, Omid
Brana, Irene
Lostes-Bardaji, M. Julia
Gajate, Pablo
Lopez-Criado, Maria Pilar
Swiecicki, Paul
de Miguel, Maria J.
Gil-Martin, Marta
Moreno, Victor
Muller, Aixa Elena Soyano
Ortiz, Ana Gonzalez
Sun, Dylan
Modi, Dimple
Zheng, Wenjun
Jankovic, Vladimir
Salvati, Mark
Fury, Matthew G.
Cristea, Mihaela C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →